iShares iBoxx $ High Yield Corporate Bond ETF vs Merck & Co., Inc. — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.65, while Merck & Co., Inc. trades at $126.01 (market cap $307.25B). The key difference: Merck & Co., Inc. pays a 2.73% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| HYG | MRK | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $81.32 | $129.52 |
52-Week Low | $78.72 | $77.60 |
Market Cap | — | $307.25B |
Enterprise Value | — | $350.66B |
Dividend Yield | — | 2.73% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.
The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.
Trailing returns across standard periods
Latest headlines on both assets
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →